Equillium vs Evommune
EQ and EVMN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EQ and EVMN compare
Evommune is the larger company, worth 3.5 times as much as Equillium ($313M against $90.0M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EQ | EVMN |
|---|---|---|
| Size and price | ||
| Market cap | $90.0M | $313M |
| Share price | $1.42 | $8.62 |
| Change, 1 year | 46.7% | −55.4% |
| Change, 5 years | −73.0% | – |
| Beta (5Y) | 0.44 | 0.92 |
| Employees | 14 | 48 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 31.3× |
| P/B | 1.6× | 1.1× (better) |
| FCF yield | −22.3% (better) | −23.9% |
| Profitability | ||
| Operating margin | – | −1019% |
| Net margin | – | −947% |
| FCF margin | – | −747% |
| Return on equity | −59.0% (better) | −142% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 23.40 (better) | 11.68 |
| Altman Z-score | 15.04 (better) | 6.09 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 65.8% | 95.4% |
| Held by insiders | 7.6% | 51.6% |
| Insider net buying, 12 months | −$2.7M | −$2.1M (better) |
| Short interest, % of float | 10.1% | 19.3% |
Go deeper
- EQ stock overview
- EQ income statement
- EQ valuation and score
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.